LIVIVO - Search results -

Search results

Result 1 - 10 of total 16

Search options

Article ; Online: Immunogenicity of poxvirus-based vaccines against Nipah virus.

Medina-Magües, Emily S / Lopera-Madrid, Jaime / Lo, Michael K / Spiropoulou, Christina F / Montgomery, Joel M / Medina-Magües, Lex G / Salas-Quinchucua, Cristhian / Jiménez-Mora, Angela P / Osorio, Jorge E

Scientific reports

2023 Volume 13, Issue 1, Page(s) 11384

Abstract: ... vaccinia Ankara (MVA) and raccoon pox (RCN) viral vectors expressing the NiV fusion (F) and glycoprotein (G ...

Abstract	Nipah virus (NiV), an emerging zoonotic pathogen in Southeast Asia, is transmitted from Pteropus species of fruit bats to a wide range of species, including humans, pigs, horses, dogs, and cats. NiV has killed millions of animals and caused highly fatal human outbreaks since no vaccine is commercially available. This study characterized the immunogenicity and safety of poxvirus-based Nipah vaccines that can be used in humans and species responsible for NiV transmission. Mice were vaccinated with modified vaccinia Ankara (MVA) and raccoon pox (RCN) viral vectors expressing the NiV fusion (F) and glycoprotein (G) proteins subcutaneously (SC) and intranasally (IN). Importantly, both vaccines did not induce significant weight loss or clinical signs of disease while generating high circulating neutralizing antibodies and lung-specific IgG and IgA responses. The MVA vaccine saw high phenotypic expression of effector and tissue resident memory CD8ɑ
MeSH term(s)	Animals ; Humans ; Cats ; Mice ; Dogs ; Swine ; Horses ; Nipah Virus ; Viral Vaccines ; Poxviridae ; Vaccinia virus/genetics ; Genetic Vectors/genetics ; Antibodies, Viral
Chemical Substances	Viral Vaccines ; Antibodies, Viral
Language	English
Publishing date	2023-07-14
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2615211-3
ISSN	2045-2322 ; 2045-2322
ISSN (online)	2045-2322
ISSN	2045-2322
DOI	10.1038/s41598-023-38010-2
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Immunogenicity and protective activity of mRNA vaccine candidates against yellow fever virus in animal models.

Medina-Magües, Lex G / Mühe, Janine / Jasny, Edith / Medina-Magües, Emily S / Roth, Nicole / Lopera-Madrid, Jaime / Salas-Quinchucua, Cristhian / Knuese, Cole / Petsch, Benjamin / Osorio, Jorge E

NPJ vaccines

2023 Volume 8, Issue 1, Page(s) 31

Abstract: Despite the success of the widely used attenuated yellow fever (YF) vaccine, its global supply remains a substantial barrier to implementing vaccination campaigns in endemic regions and combating emerging epidemics. In A129 mice and rhesus macaques, we ... ...

Abstract	Despite the success of the widely used attenuated yellow fever (YF) vaccine, its global supply remains a substantial barrier to implementing vaccination campaigns in endemic regions and combating emerging epidemics. In A129 mice and rhesus macaques, we evaluated the immunogenicity and protective activity of messenger RNA (mRNA) vaccine candidates encapsulated in lipid nanoparticles, expressing the pre-membrane and envelope proteins or the non-structural protein 1 of YF virus. Vaccine constructs induced humoral and cell-mediated immune responses in mice, resulting in protection against lethal YF virus infection after passive administration of serum or splenocytes from vaccinated mice. Vaccination of macaques induced sustained high humoral and cellular immune responses for at least 5 months after the second dose. Our data demonstrate that these mRNA vaccine candidates can be considered an attractive addition to the licensed YF vaccine supply based on the induction of functional antibodies correlating with protection and T-cell responses; they could alleviate the limited supply of current YF vaccines, mitigating future YF epidemics.
Language	English
Publishing date	2023-03-04
Publishing country	England
Document type	Journal Article
ISSN	2059-0105
ISSN (online)	2059-0105
DOI	10.1038/s41541-023-00629-7
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Impact of Molecular Modifications on the Immunogenicity and Efficacy of Recombinant Raccoon Poxvirus-Vectored Rabies Vaccine Candidates in Mice.

Malavé, Carly M / Lopera-Madrid, Jaime / Medina-Magües, Lex G / Rocke, Tonie E / Osorio, Jorge E

Vaccines

2021 Volume 9, Issue 12

Abstract: Rabies is an ancient disease that is responsible for approximately 59,000 human deaths annually. Bats ( ... ...

Abstract	Rabies is an ancient disease that is responsible for approximately 59,000 human deaths annually. Bats (Order
Language	English
Publishing date	2021-12-04
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2703319-3
ISSN	2076-393X
ISSN	2076-393X
DOI	10.3390/vaccines9121436
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Optimization in the expression of ASFV proteins for the development of subunit vaccines using poxviruses as delivery vectors.

Lopera-Madrid, Jaime / Medina-Magües, Lex G / Gladue, Douglas P / Borca, Manuel V / Osorio, Jorge E

Scientific reports

2021 Volume 11, Issue 1, Page(s) 23476

Abstract: African swine fever virus (ASFV) causes a highly contagious hemorrhagic disease that affects domestic pig and Eurasian wild boar populations. To date, no safe and efficacious treatment or vaccine against ASF is available. Nevertheless, there are several ... ...

Abstract	African swine fever virus (ASFV) causes a highly contagious hemorrhagic disease that affects domestic pig and Eurasian wild boar populations. To date, no safe and efficacious treatment or vaccine against ASF is available. Nevertheless, there are several reports of protection elicited by experimental vaccines based on live attenuated ASFV and some levels of protection and reduced viremia in other approaches such as DNA, adenovirus, baculovirus, and vaccinia-based vaccines. Current ASF subunit vaccine research focuses mainly on delivering protective antigens and antigen discovery within the ASFV genome. However, due to the complex nature of ASFV, expression vectors need to be optimized to improve their immunogenicity. Therefore, in the present study, we constructed several recombinant MVA vectors to evaluate the efficiency of different promoters and secretory signal sequences in the expression and immunogenicity of the p30 protein from ASFV. Overall, the natural poxvirus PrMVA13.5L promoter induced high levels of both p30 mRNA and specific anti-p30 antibodies in mice. In contrast, the synthetic PrS5E promoter and the S E/L promoter linked to a secretory signal showed lower mRNA levels and antibodies. These findings indicate that promoter selection may be as crucial as the antigen used to develop ASFV subunit vaccines using MVA as the delivery vector.
MeSH term(s)	African Swine Fever/virology ; African Swine Fever Virus/genetics ; Animals ; Antibodies, Viral/genetics ; Baculoviridae/genetics ; Cell Line ; Chlorocebus aethiops ; Female ; Mice ; Mice, Inbred BALB C ; Poxviridae/genetics ; Promoter Regions, Genetic/genetics ; Swine ; Vaccines, Attenuated/genetics ; Vaccines, Subunit/genetics ; Vero Cells ; Viral Proteins/genetics ; Viral Vaccines/genetics ; Virus Replication/genetics
Chemical Substances	Antibodies, Viral ; Vaccines, Attenuated ; Vaccines, Subunit ; Viral Proteins ; Viral Vaccines
Language	English
Publishing date	2021-12-06
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S.
ZDB-ID	2615211-3
ISSN	2045-2322 ; 2045-2322
ISSN (online)	2045-2322
ISSN	2045-2322
DOI	10.1038/s41598-021-02949-x
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Immunogenicity of poxvirus-based vaccines against Nipah virus

Emily S. Medina-Magües / Jaime Lopera-Madrid / Michael K. Lo / Christina F. Spiropoulou / Joel M. Montgomery / Lex G. Medina-Magües / Cristhian Salas-Quinchucua / Angela P. Jiménez-Mora / Jorge E. Osorio

Scientific Reports, Vol 13, Iss 1, Pp 1-

2023 Volume 15

Abstract: ... vaccinia Ankara (MVA) and raccoon pox (RCN) viral vectors expressing the NiV fusion (F) and glycoprotein (G ...

Abstract	Abstract Nipah virus (NiV), an emerging zoonotic pathogen in Southeast Asia, is transmitted from Pteropus species of fruit bats to a wide range of species, including humans, pigs, horses, dogs, and cats. NiV has killed millions of animals and caused highly fatal human outbreaks since no vaccine is commercially available. This study characterized the immunogenicity and safety of poxvirus-based Nipah vaccines that can be used in humans and species responsible for NiV transmission. Mice were vaccinated with modified vaccinia Ankara (MVA) and raccoon pox (RCN) viral vectors expressing the NiV fusion (F) and glycoprotein (G) proteins subcutaneously (SC) and intranasally (IN). Importantly, both vaccines did not induce significant weight loss or clinical signs of disease while generating high circulating neutralizing antibodies and lung-specific IgG and IgA responses. The MVA vaccine saw high phenotypic expression of effector and tissue resident memory CD8ɑ+ T cells in lungs and splenocytes along with the expression of central memory CD8ɑ+ T cells in lungs. The RCN vaccine generated effector memory (SC) and tissue resident (IN) CD8ɑ+ T cells in splenocytes and tissue resident (IN) CD8ɑ+ T cells in lung cells. These findings support MVA-FG and RCN-FG viral vectors as promising vaccine candidates to protect humans, domestic animals, and wildlife from fatal disease outcomes and to reduce the global threat of NiV.
Keywords	Medicine ; R ; Science ; Q
Subject code	630
Language	English
Publishing date	2023-07-01T00:00:00Z
Publisher	Nature Portfolio
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: mRNA Vaccine Protects against Zika Virus.

Medina-Magües, Lex G / Gergen, Janina / Jasny, Edith / Petsch, Benjamin / Lopera-Madrid, Jaime / Medina-Magües, Emily S / Salas-Quinchucua, Cristhian / Osorio, Jorge E

Vaccines

2021 Volume 9, Issue 12

Abstract: Zika virus (ZIKV), a mosquito-borne flavivirus, has recently triggered global concern due to severe health complications. In 2015, a large ZIKV outbreak occurred in the Americas and established a link between ZIKV and microcephaly in newborn babies, ... ...

Abstract	Zika virus (ZIKV), a mosquito-borne flavivirus, has recently triggered global concern due to severe health complications. In 2015, a large ZIKV outbreak occurred in the Americas and established a link between ZIKV and microcephaly in newborn babies, spontaneous abortion, persistent viremia, and Guillain-Barré syndrome. While antivirals are being developed and prevention strategies focus on vector control, a safe and effective Zika vaccine remains unavailable. Messenger RNA (mRNA) vaccine technology has arisen as a flexible, simplified, and fast vaccine production platform. Here, we report on an mRNA vaccine candidate that encodes the pre-membrane and envelope (prM-E) glycoproteins of ZIKV strain Brazil SPH2015 and is encapsulated in lipid nanoparticles (LNPs). Our ZIKV prM-E mRNA-LNP vaccine candidate induced antibody responses that protected in AG129 mice deficient in interferon (IFN) alpha/beta/gamma (IFN-α/β/γ) receptors. Notably, a single administration of ZIKV prM-E mRNA-LNP protected against a lethal dose of ZIKV, while a two-dose strategy induced strong protective immunity. E-specific double-positive IFN-γ and TNF-α T-cells were induced in BALB/c mice after immunizations with a two-dose strategy. With the success of mRNA vaccine technology in facing the coronavirus (COVID-19) pandemic, our data support the development of prM-E RNActive
Language	English
Publishing date	2021-12-10
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2703319-3
ISSN	2076-393X
ISSN	2076-393X
DOI	10.3390/vaccines9121464
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: mRNA Vaccine Protects against Zika Virus

Lex G. Medina-Magües / Janina Gergen / Edith Jasny / Benjamin Petsch / Jaime Lopera-Madrid / Emily S. Medina-Magües / Cristhian Salas-Quinchucua / Jorge E. Osorio

Vaccines, Vol 9, Iss 1464, p

2021 Volume 1464

Abstract	Zika virus (ZIKV), a mosquito-borne flavivirus, has recently triggered global concern due to severe health complications. In 2015, a large ZIKV outbreak occurred in the Americas and established a link between ZIKV and microcephaly in newborn babies, spontaneous abortion, persistent viremia, and Guillain–Barré syndrome. While antivirals are being developed and prevention strategies focus on vector control, a safe and effective Zika vaccine remains unavailable. Messenger RNA (mRNA) vaccine technology has arisen as a flexible, simplified, and fast vaccine production platform. Here, we report on an mRNA vaccine candidate that encodes the pre-membrane and envelope (prM–E) glycoproteins of ZIKV strain Brazil SPH2015 and is encapsulated in lipid nanoparticles (LNPs). Our ZIKV prM–E mRNA-LNP vaccine candidate induced antibody responses that protected in AG129 mice deficient in interferon (IFN) alpha/beta/gamma (IFN-α/β/γ) receptors. Notably, a single administration of ZIKV prM–E mRNA-LNP protected against a lethal dose of ZIKV, while a two-dose strategy induced strong protective immunity. E-specific double-positive IFN-γ and TNF-α T-cells were induced in BALB/c mice after immunizations with a two-dose strategy. With the success of mRNA vaccine technology in facing the coronavirus (COVID-19) pandemic, our data support the development of prM–E RNActive ® as a promising mRNA vaccine against Zika to counter future epidemics.
Keywords	AG129 ; challenge ; flavivirus ; lipid nanoparticles ; mice ; mRNA vaccines ; Medicine ; R
Language	English
Publishing date	2021-12-01T00:00:00Z
Publisher	MDPI AG
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Optimization in the expression of ASFV proteins for the development of subunit vaccines using poxviruses as delivery vectors

Jaime Lopera-Madrid / Lex G. Medina-Magües / Douglas P. Gladue / Manuel V. Borca / Jorge E. Osorio

Scientific Reports, Vol 11, Iss 1, Pp 1-

2021 Volume 12

Abstract: Abstract African swine fever virus (ASFV) causes a highly contagious hemorrhagic disease that affects domestic pig and Eurasian wild boar populations. To date, no safe and efficacious treatment or vaccine against ASF is available. Nevertheless, there are ...

Abstract	Abstract African swine fever virus (ASFV) causes a highly contagious hemorrhagic disease that affects domestic pig and Eurasian wild boar populations. To date, no safe and efficacious treatment or vaccine against ASF is available. Nevertheless, there are several reports of protection elicited by experimental vaccines based on live attenuated ASFV and some levels of protection and reduced viremia in other approaches such as DNA, adenovirus, baculovirus, and vaccinia-based vaccines. Current ASF subunit vaccine research focuses mainly on delivering protective antigens and antigen discovery within the ASFV genome. However, due to the complex nature of ASFV, expression vectors need to be optimized to improve their immunogenicity. Therefore, in the present study, we constructed several recombinant MVA vectors to evaluate the efficiency of different promoters and secretory signal sequences in the expression and immunogenicity of the p30 protein from ASFV. Overall, the natural poxvirus PrMVA13.5L promoter induced high levels of both p30 mRNA and specific anti-p30 antibodies in mice. In contrast, the synthetic PrS5E promoter and the S E/L promoter linked to a secretory signal showed lower mRNA levels and antibodies. These findings indicate that promoter selection may be as crucial as the antigen used to develop ASFV subunit vaccines using MVA as the delivery vector.
Keywords	Medicine ; R ; Science ; Q
Subject code	570
Language	English
Publishing date	2021-12-01T00:00:00Z
Publisher	Nature Portfolio
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Impact of Molecular Modifications on the Immunogenicity and Efficacy of Recombinant Raccoon Poxvirus-Vectored Rabies Vaccine Candidates in Mice

Carly M. Malavé / Jaime Lopera-Madrid / Lex G. Medina-Magües / Tonie E. Rocke / Jorge E. Osorio

Vaccines, Vol 9, Iss 1436, p

2021 Volume 1436

Abstract: Rabies is an ancient disease that is responsible for approximately 59,000 human deaths annually. Bats (Order Chiroptera ) are thought to be the original hosts of rabies virus (RABV) and currently account for most rabies cases in wildlife in the Americas. ...

Abstract	Rabies is an ancient disease that is responsible for approximately 59,000 human deaths annually. Bats (Order Chiroptera ) are thought to be the original hosts of rabies virus (RABV) and currently account for most rabies cases in wildlife in the Americas. Vaccination is being used to manage rabies in other wildlife reservoirs like fox and raccoon, but no rabies vaccine is available for bats. We previously developed a recombinant raccoonpox virus (RCN) vaccine candidate expressing a mosaic glycoprotein (MoG) gene that protected mice and big brown bats when challenged with RABV. In this study, we developed two new recombinant RCN candidates expressing MoG (RCN-tPA-MoG and RCN-SS-TD-MoG) with the aim of improving RCN-MoG. We assessed and compared in vitro expression, in vivo immunogenicity, and protective efficacy in vaccinated mice challenged intracerebrally with RABV. All three candidates induced significant humoral immune responses, and inoculation with RCN-tPA-MoG or RCN-MoG significantly increased survival after RABV challenge. These results demonstrate the importance of considering molecular elements in the design of vaccines, and that vaccination with either RCN-tPA-MoG or RCN-MoG confers adequate protection from rabies infection, and either may be a sufficient vaccine candidate for bats in future work.
Keywords	rabies ; rabies virus ; RABV ; raccoon poxvirus ; recombinant ; vaccine ; Medicine ; R
Subject code	570
Language	English
Publishing date	2021-12-01T00:00:00Z
Publisher	MDPI AG
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Clinical Presentation and Serologic Response during a Rabies Epizootic in Captive Common Vampire Bats

Cárdenas-Canales, Elsa M / Gigante, Crystal M / Greenberg, Lauren / Velasco-Villa, Andres / Ellison, James A / Satheshkumar, Panayampalli S / Medina-Magües, Lex G / Griesser, Richard / Falendysz, Elizabeth / Amezcua, Ignacio / Osorio, Jorge E / Rocke, Tonie E

Tropical medicine and infectious disease

2020 Volume 5, Issue 1

Abstract: We report mortality events in a group of 123 common vampire bats ( ...

Abstract	We report mortality events in a group of 123 common vampire bats (
Language	English
Publishing date	2020-03-01
Publishing country	Switzerland
Document type	Case Reports
ISSN	2414-6366
ISSN (online)	2414-6366
DOI	10.3390/tropicalmed5010034
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED